MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The Parkinson’s Disease Composite of Executive-Functioning (PaCEF): A measure for detecting cognitive decline for Parkinson’s disease clinical trials

C. Young, B. Cholerton, M. Shahid, C. Abdelnour, C. Zabetian, T. Montine, K. Poston (Stanford, USA)

Meeting: 2023 International Congress

Abstract Number: 399

Keywords: Cognitive dysfunction, Executive functions, Parkinson’s

Category: Parkinson's Disease: Cognitive functions

Objective: To develop a cognitive composite measure that is sensitive to decline in executive functioning for use in Parkinson’s disease (PD) clinical trials.

Background: The affected cognitive domains and course of cognitive decline are different for PD and Alzheimer’s disease; however, PD clinical trials have measured cognitive decline primarily using composites designed for Alzheimer’s disease. Developing cognitive measures specifically assessing executive functioning is of critical importance given that this domain is often the first to be impaired in PD [1] and up to 80% of PD patients go on to develop dementia [2].

Method: To create the PaCEF, we applied confirmatory factor analysis to baseline neuropsychological data from 841 PD participants enrolled in the Pacific Udall Consortium (Table 1). In 545 PD participants with longitudinal data (Table 2), we used linear mixed models to quantify cognitive decline detected by the PaCEF and MoCA. Logistic regression was used to examine how well the PaCEF and MoCA predicts cognitive progression and time to progression. We calculated the sample sizes required for future clinical trials to detect a 25-50% reduction in slope of cognitive decline over 1 or 2 years using the PaCEF and MoCA.

Results: A one-factor model of executive functioning with excellent fit (Fig 1; CFI=0.993, TLI=0.989, RMSEA=0.044) was used to calculate the PaCEF. The average annual change in PaCEF ranged from virtually no change for cognitively unimpaired (CU) participants who did not progress to over 2 points for mild cognitive impairment (MCI) participants who progressed to dementia (Fig 2). For CU participants, baseline MoCA but not baseline PaCEF was significantly associated with subsequent cognitive progression (Table 3). In contrast, for MCI participants, baseline PaCEF but not baseline MoCA was significantly associated with progression to dementia (Table 3). The PaCEF showed the strongest association with predicting time to dementia. Sample size comparisons demonstrate a clear advantage of using the PaCEF as an endpoint, with a 43% reduction in required sample size in comparison to the MoCA, assuming a 25% or 50% reduction in slopes.

Conclusion: The PaCEF is a sensitive measure of executive function decline in PD that will be especially beneficial for clinical trials focused on PD-MCI patients.

EFComposite MDSAbstract Table1

EFComposite MDSAbstract Table2

EFComposite MDSAbstract Table3

EFComposite MDSAbstract Figure1

EFComposite MDSAbstract Figure2

References: 1. Weintraub D, Tröster AI, Marras C, Stebbins G. Initial cognitive changes in Parkinson’s disease. Movement Disorders. 2018;33(4):511–9.
2. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217–31.

To cite this abstract in AMA style:

C. Young, B. Cholerton, M. Shahid, C. Abdelnour, C. Zabetian, T. Montine, K. Poston. The Parkinson’s Disease Composite of Executive-Functioning (PaCEF): A measure for detecting cognitive decline for Parkinson’s disease clinical trials [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/the-parkinsons-disease-composite-of-executive-functioning-pacef-a-measure-for-detecting-cognitive-decline-for-parkinsons-disease-clinical-trials/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-parkinsons-disease-composite-of-executive-functioning-pacef-a-measure-for-detecting-cognitive-decline-for-parkinsons-disease-clinical-trials/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley